Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)-Reference-Cited by-同舟云学术

Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)

Published:2017-02-06 Issue:3 Volume:6 Page:409-414
ISSN:2049-9450
Container-title:Molecular and Clinical Oncology
language:en
Short-container-title:

Author:

Miyawaki Masayoshi,Naoki Katsuhiko,Yoda Satoshi,Nakayama Sohei,Satomi Ryosuke,Sato Takashi,Ikemura Shinnosuke,Ohgino Keiko,Ishioka Kota,Arai Daisuke,Namkoong Ho,Otsuka Kengo,Miyazaki Masaki,Tani Tetsuo,Kuroda Aoi,Nishino Makoto,Yasuda Hiroyuki,Kawada Ichiro,Koh Hidefumi,Nakamura Morio,Terashima Takeshi,Sakamaki Fumio,Sayama Koichi,Betsuyaku Tomoko,Soejima Kenzo

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Predicting Treatment Response Before EGFR TKI Treatment in Patients with Advanced Lung Adenocarcinoma;Molecular Imaging and Radionuclide Therapy;2022-06-01

2. The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China;Frontiers in Pharmacology;2022-03-16

3. 177Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials;Biomedicines;2021-08-19

4. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China;Pharmacology;2021

5. Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis;PLOS ONE;2020-07-14